Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3054
Abstract: This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera®) combined with CHOP as the first‐line treatment for Chinese patients with CD20‐positive diffuse large B cell lymphoma (DLBCL). This is a… read more here.
Keywords: cd20 positive; safety; chop; rituximab mabthera ... See more keywords
R‐CHOP VS. R‐CHOP+X FOR NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META‐ANALYSIS
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.95_2631
Abstract: cancer specific survival and overall survival respectively were 86%, 71% and 57%. Conclusion: A trend for an improvement in all outcomes was found for patients treated with a DS of 1-3, compared to a DS… read more here.
Keywords: newly diagnosed; chop newly; diffuse large; chop chop ... See more keywords